Participated · Equity · Apr 2024

Curida Holding AS is an integrated contract development and manufacturing organization (CDMO) headquartered in Oslo, Norway, founded in 2015. It offers contract development and GMP manufacturing solutions for small-molecule pharmaceuticals and biologics, focusing on aseptic and non-aseptic liquid manufacturing and specializing in blow-fill-seal (BFS) and nasal spray technologies. For biologics, Curida provides upstream and downstream processing of monoclonal antibodies for in‑vitro diagnostics. Its customer base ranges from small to medium-sized pharmaceutical and biotech companies, serving European clients globally. The company plans to accelerate expansion and enhance facility capabilities following a new investment to grow its industry position. Recent corporate changes include Signet joining the board, Ole J. Dahlberg appointed Chairman, and Anders Larsson named CEO effective May 1, 2024.

Led · Series A · Jun 2023

Cytovation is a clinical-stage immune-oncology company developing CyPep-1, an immunotherapy that targets the cell membrane of tumor cells. CyPep-1 has a multi-modal mechanism of action: it forms pores in the plasma membrane to eliminate cancer cells, releases antigens to the immune system, promotes an inflammatory microenvironment, and induces a tumor-specific immune response by in situ vaccination. The company is advancing CyPep-1 toward treatment of solid tumors and plans to move the asset into a full Phase 2 program. Cytovation is led by CEO Lars Prestegarden, MD, PhD, and is a spin-off from the University of Bergen. Financially, the company recently completed an $8M Series A extension that increased total Series A funding to over $28M. Cytovation is a clinical-stage immune-oncology company and spin-off from the University of Bergen focused on developing CyPep-1, a first-in-class tumorolytic agent that targets the plasma membrane of cancer cells. CyPep-1 is engineered to selectively target cancer cells and kill them by forming pores in the plasma membrane, releasing cancer-specific antigens to the immune system. That release promotes an inflammatory tumor microenvironment and induces a tumor-specific immune response described as in situ vaccination. Preclinical data cited by the company suggest this mode of action is highly synergistic with checkpoint inhibitors. Cytovation plans to progress CyPep-1 into Phase II, expanding single-agent arms and adding three combination arms with KEYTRUDA (pembrolizumab) in HNSCC, triple-negative breast cancer, and melanoma in collaboration with MSD. The company intends to use financing proceeds to advance CyPep-1 and explore further pipeline development targeting patients with high unmet medical need. Cytovation develops CyPep-1, a 27–amino-acid peptide that selectively targets cutaneous warts by disrupting the cell membrane and triggering an immune response through antigen release. The company intends to formulate CyPep-1 as a topical cream for treatment of warts caused by human papilloma virus (HPV) and sees applications in other dermatological diseases. Cytovation says the approach is a completely novel treatment strategy and that the product has already undergone extensive testing and quality control. The company will use the new funding to complete pre-clinical toxicology studies and GMP manufacturing and to advance CyPep-1 into a Phase I clinical trial. Cytovation is led by CEO Kjell Inge Arnevig and has ties to Haukeland University Hospital and the University of Bergen. The company was founded in 2001 and is based in Bergen, Norway.

Participated · Equity · Jun 2021

Oncoinvent is a clinical-stage company developing radiopharmaceutical technology that delivers alpha-emitting particles to treat metastatic solid cancers. Its lead candidate, Radspherin®, is a radium-224 based alpha-emitting microsphere suspension in ongoing Phase 1 trials for peritoneal carcinomatosis from ovarian and colorectal cancer. The company leverages internal manufacturing and supply-chain capabilities to enable clinical supply of radioisotopes and is advancing a pipeline of targeted radiotherapeutics. Proceeds from the recent financing will fund two planned Phase 2A studies (ovarian and colorectal cancer) and accelerate preclinical development of proprietary antibodies OI-1 and OI-3 by about one year. Oncoinvent has raised NOK 535 million to date and says the new proceeds secure financing past the end of 2023. The company intends to pursue a contemplated initial public offering within the coming twelve months. Oncoinvent is an Oslo, Norway–based developer of new products to provide treatment options to cancer patients. Its lead candidate, Radspherin®, is a radium-224–based, alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. Preclinical studies have shown anticancer activity at doses that were essentially non-toxic. The company will use the funds from the financing to pursue clinical development of Radspherin® and to advance other novel radiopharmaceuticals. Oncoinvent is led by CEO Jan A. Alfheim and is focused on translating its preclinical results into clinical programs. No revenue or user metrics were reported in the article. Oncoinvent is an Oslo, Norway–based developer of cancer therapeutics led by CEO Jan A. Alfheim. Its lead product, Radspherin™, is a novel alpha-emitting radioactive microsphere based on radium designed for treatment of metastatic cancers in body cavities. Preclinical studies of Radspherin showed consistent anticancer activity without any visible signs of product-related toxicity. The company plans to pursue clinical development, with the first clinical indication being treatment of peritoneal carcinomatosis originating from ovarian cancer. Financially, Oncoinvent raised around $25m in new equity funding to support its development programs. Backers in the round included Geveran Trading, Canica, CGS Holding, Helene Sundt and Must Invest.

Participated · Equity · Sep 2020

Galecto is a clinical-stage biopharma focused on creating first-in-class treatments for cancer and liver diseases. Through its acquisition of Damora Therapeutics, Galecto has added a portfolio of antibody therapies that target mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs) such as Essential Thrombocythemia and Myelofibrosis. The lead asset, DMR-001, is a potentially best-in-class anti-mutCALR monoclonal antibody engineered for subcutaneous dosing and is expected to file an IND in mid-2026, with Phase 1 proof-of-concept data anticipated in 2027. Two additional antibodies, DMR-002 and DMR-003, are slated to enter Phase 1 studies thereafter. Galecto’s legacy pipeline also includes GB3226, a dual ENL-YEATS and FLT3 inhibitor being advanced toward an IND submission in Q1 2026 for acute myeloid leukemia. Following the $284.9 million private placement completed alongside the Damora acquisition, management projects a cash runway into 2029, sufficient to reach multiple clinical readouts. After conversion of the new preferred shares, Galecto will have 61,998,882 common shares outstanding.

Participated · Series A · Jan 2018

Arundo Analytics builds cloud-based, edge-enabled software to deploy and manage enterprise-scale industrial data science and machine learning. Its platform is purpose-built for deep industrial data science and enables applications such as equipment monitoring and sensor anomaly detection. The company targets operators, OEMs and service companies in asset-heavy sectors that struggle to capitalize on operational data due to legacy assets and harsh operating conditions. Arundo cites a heritage in the maritime industry and says its software lets customers drive business value from operating data in days or weeks rather than months or years. It plans to use the new financing to expand sales and marketing across oil & gas, maritime, mining, chemicals, power and manufacturing, and to grow engineering and data science teams in Houston, Oslo and Palo Alto, with recent hires in Lausanne and London. Financially, Arundo announced an initial closing of a $25 million Series A and has raised over $32.5 million since its 2015 founding.